| Bioactivity | NSC 405020 is a specific MMP14 inhibitor. NSC 405020 can directly interact with the hemopexin domain of MMP14. NSC 405020 reduces the expression of full length and active cleaved Notch3 (NICD3). NSC 405020 can be used to research vestibular schwannoma, hemostasis and thrombosis[1][2][3]. | ||||||||||||
| Target | MMP14 | ||||||||||||
| Invitro | NSC 405020 (100 and 1000 μM; 0-30 min) inhibits MMP-14 levels by over 85% with a dose-dependent manner in the plasma sample from vestibular schwannoma group[1].NSC 405020 (50 μM) reduces expression of the full length and active cleaved Notch3 (NICD3) by 42% in the WM852 cells[2]. | ||||||||||||
| Name | NSC 405020 | ||||||||||||
| CAS | 7497-07-6 | ||||||||||||
| Formula | C12H15Cl2NO | ||||||||||||
| Molar Mass | 260.16 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Ren Y, et al. MMP-14 (MT1-MMP) Is a Biomarker of Surgical Outcome and a Potential Mediator of Hearing Loss in Patients With Vestibular Schwannomas. Front Cell Neurosci. 2020 Jul 28;14:191. [2]. Pekkonen P, et al. Lymphatic endothelium stimulates melanoma metastasis and invasion via MMP14-dependent Notch3 and β1-integrin activation. Elife. 2018 May 1;7:e32490. [3]. Mastenbroek TG, et al. Platelet-Associated Matrix Metalloproteinases Regulate Thrombus Formation and Exert Local Collagenolytic Activity. Arterioscler Thromb Vasc Biol. 2015 Dec;35(12):2554-61. |
NSC 405020
CAS: 7497-07-6 F: C12H15Cl2NO W: 260.16
NSC 405020 is a specific MMP14 inhibitor. NSC 405020 can directly interact with the hemopexin domain of MMP14. NSC 40502
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.